Johnson & Johnson vs Sanofi (JNJ vs SAN.PA)
Sanofi trades at 24.3x earnings vs 41.4x for Johnson & Johnson; Sanofi grows sales faster (+15.7% vs +5.9%). Margins, debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Sanofi looks cheaper on P/E: 24.3x against 41.4x for Johnson & Johnson. Sanofi grows faster: sales +15.7% against +5.9% for Johnson & Johnson in the latest quarter. Johnson & Johnson has the better net margin: 16.2% against 8.2% for Sanofi.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Johnson & Johnson is the more expensive of the two: it trades at 41.4x its annual earnings against 24.3x for Sanofi. Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Johnson & Johnson sales +5.9% against +15.7% for Sanofi in the latest quarter; net margin 16.2% against 8.2%; net debt for Johnson & Johnson: 0.8x EBITDA against 0.9x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Johnson & Johnson (JNJ) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Johnson & Johnson and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Johnson & Johnson or Sanofi.
Johnson & Johnson vs Sanofi: the figures
| Figure | Johnson & Johnson | Sanofi |
|---|---|---|
| Share price | $272.70 (November 18, 2026) | €84.08 (November 19, 2026) |
| Market cap | $656.5 billion | €100.9 billion |
| P/E (TTM) | 41.4x | 24.3x |
| Forward P/E | 23.5x | 8.8x |
| Revenue growth (quarter) | +5.9% | +15.7% |
| Net margin (TTM) | 16.2% | 8.2% |
| Net debt / EBITDA | 0.8x | 0.9x |
| Dividend yield | 1.97% | 4.76% |
| Beta | 0.20 | 0.26 |
Johnson & Johnson and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Johnson & Johnson or Sanofi figure is not available, and we never estimate it.
3 key differences between Johnson & Johnson and Sanofi
- Valuation: Johnson & Johnson trades at 41.4x its annual earnings and Sanofi at 24.3x; the market pays more for each dollar of Johnson & Johnson profit, usually because it expects more growth.
- Dividend: Sanofi yields 4.76% at today's price and Johnson & Johnson yields 1.97%.
- Profitability: for every 100 of sales, Johnson & Johnson keeps 16.2 as net profit and Sanofi keeps 8.2.
Johnson & Johnson or Sanofi: which fits your profile
- If you want growth: Sanofi is growing faster today, with sales +15.7% against +5.9% for Johnson & Johnson and also trades on a lower P/E (24.3x against 41.4x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Sanofi pays the higher dividend relative to its price.
- If you prefer caution: Johnson & Johnson has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Sanofi trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Johnson & Johnson nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Johnson & Johnson or Sanofi?
Of the 6 comparable figures in the table, Johnson & Johnson stands out on 3 (net margin, less debt over EBITDA and lower volatility (beta)) and Sanofi stands out on 3 (sales growth, lower P/E and dividend yield). That does not name a winner between Johnson & Johnson and Sanofi: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Johnson & Johnson vs Sanofi (JNJ vs SAN.PA)”.
No card required
Johnson & Johnson vs Sanofi by dimension
Strategy
Johnson & Johnson operates in healthcare and pharma and Sanofi in healthcare and pharma, so they only fight for the same customer when the sector overlaps.
Products and AI
Johnson & Johnson and Sanofi sell different things: Johnson & Johnson reports two segments. And for Sanofi: Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines.
Margins
Johnson & Johnson is more profitable: it keeps 16.2 of every 100 it sells, against 8.2 for Sanofi.
Valuation
Johnson & Johnson trades at the higher P/E (41.4x against 24.3x for Sanofi). A higher P/E is only justified if earnings grow faster.
Risks
Sanofi is the more volatile: beta 0.26 against 0.20 for Johnson & Johnson.
Competitors
Other companies investors compare Johnson & Johnson and Sanofi with: Intuitive Surgical, Medtronic, Bayer, argenx. Intuitive Surgical · Medtronic · Bayer · argenx
How Johnson & Johnson and Sanofi make money
Johnson & Johnson (JNJ)
Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. MedTech sells orthopedic devices through DePuy Synthes, surgical tools, cardiovascular products from Abiomed and Shockwave, and vision care. The U.S. is its largest market. Full Johnson & Johnson analysis.
Sanofi (SAN.PA)
Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets. Full Sanofi analysis.
Frequently asked questions: Johnson & Johnson vs Sanofi
What is the difference between Johnson & Johnson and Sanofi?
Johnson & Johnson reports two segments. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. Both are in healthcare and pharma. As of November 19, 2026: P/E 41.4 vs 24.3; net margin 16% vs 8% (Johnson & Johnson vs Sanofi).
Is Johnson & Johnson or Sanofi the better stock?
Choosing between Johnson & Johnson and Sanofi depends on what you are looking for. Sanofi is growing faster right now, and Sanofi trades on the lower P/E. Fintols does not tell you whether to buy Johnson & Johnson or Sanofi: it shows you the differences so you can decide.
Which pays a higher dividend, Johnson & Johnson or Sanofi?
As of November 19, 2026, Sanofi yields 4.76% and Johnson & Johnson yields 1.97%. Also check how much of their profit Johnson & Johnson and Sanofi pay out: if it is more than they earn, it cannot last.
Which is more expensive, Johnson & Johnson or Sanofi?
On P/E, Johnson & Johnson (41.4x) is more expensive than Sanofi (24.3x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Johnson & Johnson or Sanofi?
On net margin, Johnson & Johnson (16.2%) keeps more of every 100 it sells than Sanofi (8.2%), as of November 19, 2026.
Which has more debt, Johnson & Johnson or Sanofi?
As of November 19, 2026, Sanofi owes 0.9x its EBITDA and Johnson & Johnson owes 0.8x its EBITDA (net debt over EBITDA).
Can I own both Johnson & Johnson and Sanofi?
Yes. Many people spread their money across several companies, such as Johnson & Johnson and Sanofi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Johnson & Johnson or Sanofi.
To go deeper: Does Johnson & Johnson pay a dividend? and Does Sanofi pay a dividend?.
Related comparisons for Johnson & Johnson and Sanofi
- Intuitive Surgical vs Johnson & Johnson
- Johnson & Johnson vs Medtronic
- Johnson & Johnson vs Merck
- Johnson & Johnson vs Eli Lilly
More companies like Johnson & Johnson and Sanofi: healthcare and pharma stocks. Educational content about Johnson & Johnson and Sanofi, not investment advice.
Full analyses: Johnson & Johnson and Sanofi. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Johnson & Johnson or Sanofi.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card